Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1567702 | 0.85 | ALDH1A1 (0.46) | NPC1POLBALDH1A1L3MBTL1 | |
| SCHEMBL1568835 | 0.81 | PTK2 (0.42) | KMT2ANPC1MAPTMEN1 | |
| SCHEMBL1082378 | 0.79 | ALDH1A1 (0.49) | HPGDKMT2ANPC1POLBMAPK1 | |
| SCHEMBL459541 | 0.69 | PSMB8 (0.68) | NPC1TSHR | |
| SCHEMBL5544281 | 0.69 | NOTUM (0.53) | HPGDNPC1MAPK1TSHRALDH1A1 | |
| SCHEMBL1935798 | 0.69 | — | — | |
| SCHEMBL627518 | 0.66 | MAPK1 (0.44) | HPGDNPC1MAPTMAPK1ALDH1A1 | |
| SCHEMBL30578691 | 0.66 | NPC1 (0.55) | HPGDKMT2ANPC1ALOX12POLB | |
| SCHEMBL1106684 | 0.65 | IDO1 (0.58) | KMT2AMAPTTSHRALDH1A1MEN1 | |
| SCHEMBL10364620 | 0.64 | NPC1 (0.54) | HPGDKMT2ANPC1ALOX12POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071663-A1 | Preparation of N'-(4--2,5-dimethylphenyl)-N- ethyl-N-methylimidoformamide | BAYER CROPSCIENCE AG (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071663-A1 | Preparation of N'-(4--2,5-dimethylphenyl)-N- ethyl-N-methylimidoformamide | BAYER CROPSCIENCE AG (DE) | 2012-03-22 | — | — | US | disclosed |
| WO-2012019998-A1 | PRODUCTION OF N'-(4-{[3-(4-CHLORBENZYL)-1,2,4-THIADIAZOL-5-YL] OXY} -2,5-DIMETHYLPHENYL)-N-ETHYL-N-METHYLIMIDOFORMAMIDE | BAYER CROPSCIENCE AG (DE) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071663-A1 | Preparation of N'-(4--2,5-dimethylphenyl)-N- ethyl-N-methylimidoformamide | NT5C, NT5E, NT5C3B | HPGD 1172/4885KMT2A 144/4885NPC1 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.